Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.
AMIA Annu Symp Proc
; 2018: 1093-1102, 2018.
Article
em En
| MEDLINE
| ID: mdl-30815151
ABSTRACT
We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results:
(a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Terapia Assistida por Computador
/
Biologia Computacional
/
Medicina de Precisão
/
Terapia de Alvo Molecular
/
Bevacizumab
/
Antineoplásicos Imunológicos
/
Carcinoma Epitelial do Ovário
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Female
/
Humans
Idioma:
En
Revista:
AMIA Annu Symp Proc
Assunto da revista:
INFORMATICA MEDICA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos